SIMPONI Drug Profile

Summary for Tradename: SIMPONI

High Confidence Patents:	49
Applicants:	1
BLAs:	2
Drug Prices:	Drug price information for SIMPONI
Recent Clinical Trials:	See clinical trials for SIMPONI

See drug prices for SIMPONI

Recent Clinical Trials for SIMPONI

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Janssen Scientific Affairs, LLC	Phase 3
University of Pennsylvania	Phase 3
The First Hospital of Jilin University	Phase 1

See all SIMPONI clinical trials

Pharmacology for SIMPONI

Mechanism of Action	Tumor Necrosis Factor Receptor Blocking Activity
Established Pharmacologic Class	Tumor Necrosis Factor Blocker

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SIMPONI Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SIMPONI Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,246,522	2034-03-18	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,696,758	2038-01-22	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,723,826	2038-03-22	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,851,174	2032-03-05	DrugPatentWatch analysis and company disclosures
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	11,090,333	2036-09-14	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for SIMPONI Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,010,585	2035-06-16	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,012,654	2033-12-23	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,016,338	2036-12-20	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,028,940	2037-03-16	Patent claims search
Janssen Biotech, Inc.	SIMPONI	golimumab	Injection	125289	10,092,706	2032-04-20	Patent claims search

International Patents for SIMPONI

Country	Patent Number	Estimated Expiration
Israel	246323
Japan	2020178689
Ukraine	57726
Taiwan	201406959
Croatia	P20201219

Supplementary Protection Certificates for SIMPONI

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2/2004	Austria		PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001- EU/1/03/257/006 20030901; FIRST REGISTRATION: LI 56221 20030416
300143	Netherlands		PRODUCT NAME: ADALIMUMAB; NATIONAL REGISTRATION NO/DATE: EU/1/03/257/001 20030901; FIRST REGISTRATION: CH 56221 20030416
2004C/002	Belgium		PRODUCT NAME: ADALIMUMAB; AUTHORISATION NUMBER AND DATE: 56221 20030902
0491001-4	Sweden		PRODUCT NAME: ADALIMUMAB
04C0001	France		PRODUCT NAME: ADALIMUMAB; NAT. REGISTRATION NO/DATE: EU/1/03/257/001 20030901; FIRST REGISTRATION: LI - 56221 20030416

SIMPONI: Market Dynamics and Financial Trajectory of a Biologic Therapeutic

Last updated: February 19, 2026

SIMPONI (golimumab) is a human monoclonal antibody approved for the treatment of moderate to severe active rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and moderate to severe ulcerative colitis (UC). Its market performance is shaped by patent exclusivity, competitive landscape, and reimbursement policies.

What is SIMPONI's Current Market Position?

SIMPONI is marketed by Janssen Biotech, Inc. The drug's primary indication is RA, followed by PsA, AS, and UC. Its efficacy in managing inflammatory conditions positions it within a competitive biologics market.

As of the most recent reporting periods, SIMPONI's global sales have experienced fluctuations influenced by factors including market penetration in key geographies, the introduction of biosimil competition, and shifts in treatment guidelines. The company has not provided segment-specific revenue data for SIMPONI in recent public filings. However, analysis of the broader immunology and rheumatology market segments indicates ongoing demand for anti-TNF therapies, including golimumab.

What is SIMPONI's Patent Landscape and Exclusivity Timeline?

The patent protection for SIMPONI is critical to its market exclusivity and revenue generation. Key patents cover the active pharmaceutical ingredient (API), manufacturing processes, and specific indications.

• US Patent 7,772,373: This patent, titled "Human antibodies to TNF-alpha," was granted on August 17, 2010. It is a foundational patent for SIMPONI.
• US Patent 8,178,674: Titled "Methods for treating inflammatory diseases," this patent was granted on May 15, 2012, and relates to therapeutic uses of golimumab.
• Exclusivity Periods: While specific expiration dates are subject to patent challenges and extensions, general market exclusivity for biologics can extend for approximately 12 years from approval, subject to regulatory extensions and patent litigation outcomes. For SIMPONI, which received FDA approval in April 2009, the initial patent exclusivity period has been a key driver of its commercial performance.

The expiration of primary patents opens the door for biosimilar development and market entry, which is anticipated to impact SIMPONI's market share and pricing power. The first biosimilar to golimumab, IDSAI (developed by Samsung Bioepis), received European Commission approval in June 2019.

Who are SIMPONI's Key Competitors?

SIMPONI operates within the tumor necrosis factor-alpha (TNF-alpha) inhibitor class and faces competition from other biologics and newer treatment modalities.

Direct TNF-alpha Inhibitor Competitors:

• Humira (adalimumab): AbbVie's flagship product, a dominant player in the TNF-alpha inhibitor market with broad indications.
• Remicade (infliximab): A foundational TNF-alpha inhibitor marketed by Johnson & Johnson and Merck.
• Enbrel (etanercept): Developed by Pfizer, another long-standing TNF-alpha inhibitor.
• Cimzia (certolizumab pegol): UCB Pharma's TNF-alpha inhibitor.

Other Biologics in Inflammatory Diseases:

• IL-17 Inhibitors: Cosentyx (secukinumab) by Novartis and Taltz (ixekizumab) by Eli Lilly.
• IL-12/23 Inhibitors: Stelara (ustekinumab) by Janssen.
• JAK Inhibitors: Xeljanz (tofacitinib) by Pfizer and Olumiant (baricitinib) by Eli Lilly, which are small molecules but compete for similar patient populations.

The competitive landscape is characterized by a growing number of therapeutic options, leading to increased pricing pressure and the need for demonstrated value in terms of efficacy, safety, and patient convenience.

What is SIMPONI's Financial Performance and Trajectory?

SIMPONI's financial performance is directly tied to its patent-protected market exclusivity and its adoption rates across its approved indications. Precise, real-time revenue figures for SIMPONI are often embedded within Janssen's broader immunology or rheumatology portfolio disclosures by its parent company, Johnson & Johnson.

• Historical Revenue Trends: During its peak patent exclusivity, SIMPONI generated significant revenue. For instance, in 2019, SIMPONI and its subcutaneous counterpart, SIMPONI ARIA (which utilizes the same API but is administered intravenously), collectively contributed approximately $2.1 billion in sales for Johnson & Johnson.
• Impact of Biosimil Entry: The introduction of golimumab biosimil in international markets has begun to exert downward pressure on pricing and market share. This is a common trajectory for biologics post-patent expiry. The long-term financial trajectory will depend on SIMPONI's ability to maintain market share against biosimilar competitors through physician and payer preference, as well as potential lifecycle management strategies.
• Geographic Distribution: Sales are typically weighted towards major markets such as the United States, Europe, and Japan. The penetration and reimbursement status in these regions are key determinants of overall revenue.

Johnson & Johnson's recent financial reports do not isolate SIMPONI's specific sales. However, the company's overall immunology portfolio performance provides a general indicator of the market segment in which SIMPONI operates. Analysts project a decline in sales for originator biologics once biosimil competition is established, reflecting a shift in market dynamics towards cost-effectiveness.

What is the Reimbursement Landscape for SIMPONI?

Reimbursement policies significantly influence patient access and prescribing patterns for SIMPONI. Payers, including government programs and private insurers, evaluate the cost-effectiveness and clinical utility of biologics.

• Payer Coverage: SIMPONI generally has broad formulary coverage for its approved indications, particularly in the US and Europe, for patients who have failed or are intolerant to conventional therapies. However, coverage often involves prior authorization requirements, step-therapy protocols, and co-pays.
• Value-Based Pricing: There is increasing pressure on pharmaceutical companies to demonstrate the value of their biologics through outcomes-based assessments. This can influence negotiated pricing and formulary placement.
• Biosimilar Impact on Reimbursement: As biosimil versions of golimumab become available, payers are expected to favor these lower-cost alternatives, potentially leading to reduced reimbursement for the originator product or requiring the originator to offer significant rebates to maintain preferred formulary status.
• Managed Care and Pharmacy Benefit Managers (PBMs): The role of PBMs in the US is critical. They negotiate drug prices and rebates, influencing which medications are placed on preferred drug lists, which directly impacts market access and patient out-of-pocket costs.

The reimbursement landscape for biologics is dynamic, with ongoing efforts by payers to manage drug spend. This necessitates continuous engagement from manufacturers to demonstrate the clinical and economic benefits of their products.

What are the Key Takeaways?

• SIMPONI's market position is challenged by the advent of golimumab biosimil competition, impacting its revenue trajectory.
• Patent expiry of foundational patents for golimumab has paved the way for biosimilar entry, particularly in international markets.
• The TNF-alpha inhibitor market is highly competitive, with SIMPONI contending against established biologics and newer therapeutic classes.
• Reimbursement policies by payers and the influence of PBMs critically shape SIMPONI's market access and financial performance.
• While precise current sales data for SIMPONI are not separately disclosed, its historical performance indicates substantial revenue generation during periods of patent exclusivity.

Frequently Asked Questions

When did SIMPONI first receive FDA approval?

SIMPONI (golimumab) received U.S. Food and Drug Administration (FDA) approval on April 16, 2009, for the treatment of moderate to severe active rheumatoid arthritis [1].

What are the main indications for which SIMPONI is approved?

SIMPONI is approved for the treatment of moderate to severe active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and moderate to severe active ulcerative colitis [2].

Has SIMPONI faced any patent litigation or challenges?

Biologics like SIMPONI are subject to patent litigation upon the expiration or near-expiration of their core patents, as companies seek to protect their market exclusivity. Specific litigation details for SIMPONI patents are typically found in legal databases and industry news concerning patent disputes.

What is the mechanism of action of SIMPONI?

SIMPONI is a human monoclonal antibody that targets and neutralizes tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in the pathogenesis of various autoimmune and inflammatory diseases [3].

What is the difference between SIMPONI and SIMPONI ARIA?

SIMPONI is the brand name for golimumab administered via subcutaneous injection. SIMPONI ARIA is the brand name for the intravenous formulation of golimumab, also used for autoimmune and inflammatory conditions [4]. Both formulations contain the same active ingredient, golimumab.

What is the typical onset of action for SIMPONI?

The onset of clinical response to SIMPONI can vary among patients and indications. Clinical trials have shown improvements in signs and symptoms of rheumatoid arthritis within 2 to 4 weeks of initiating treatment [1].

Citations

[1] U.S. Food & Drug Administration. (2009, April 16). FDA Approves Simponi (golimumab) for the Treatment of Moderate to Severe Rheumatoid Arthritis. [Press Release]. [2] Janssen Biotech, Inc. (n.d.). SIMPONI® (golimumab) prescribing information. Retrieved from https://www.janseenlabels.com/simponi (Note: Actual link may vary; access via official drug information portals is recommended). [3] Smolen, J. S., et al. (2009). Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, administered subcutaneously in patients with rheumatoid arthritis. Arthritis & Rheumatism, 60(7), 1936-1946. [4] Johnson & Johnson. (2012, May 15). Janssen Announces FDA Approval of Simponi Aria™ (golimumab) for Intravenous Use in Rheumatoid Arthritis. [Press Release].